81,170 results match your criteria Thromboembolism


A Phase II Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab and Chemoradiotherapy in the Adjuvant Setting in Operated Patients With HER2-positive Gastric or Gastroesophageal Junction Cancer (TOXAG Study): A Turkish Oncology Group Study.

Am J Clin Oncol 2021 May 12. Epub 2021 May 12.

Department of Medical Oncology, Acibadem Adana Hospital Departments of Radiation Medical Oncology, Baskent University, Adana Department of Medical Oncology, Hacettepe University Department of Medical Oncology, Dr. A.Y. Ankara Oncology Training and Research Hospital Department of Medical Oncology, Gazi University Department of Medical Oncology, Medical Park Ankara Hospital Department of Medical Oncology, Ankara Yildirim Beyazit University, Ankara Department of Medical Oncology, Marmara University Department of Medical Oncology, Ethica Incirli Hospital Roche Pharmaceuticals Department of Medical Pharmacology, Bahcesehir University School of Medicine Department of Biostatistics and Medical Informatics, Koc University/MedStats Consulting, Istanbul Department of Medical Oncology, Necmettin Erbakan University Meram School of Medicine, Konya Department of Medical Oncology, Ege University, Izmir, Turkey.

Background: Trastuzumab prolonged the overall survival in patients with advanced gastric cancer with human epidermal growth factor receptor 2 (HER2) overexpression in combination with chemotherapy. In this phase II open-label prospective study, the tolerability and safety of trastuzumab with chemotherapy, and chemoradiotherapy for curatively resected patients with HER2-positive gastric carcinoma was investigated.

Methods: The patients with HER2-positive gastric, or gastroesophageal junction adenocarcinoma, after gastrectomy plus D2 dissection, were included. Read More

View Article and Full-Text PDF

Impact of antithrombin III and enoxaparin dosage adjustment on prophylactic anti-Xa concentrations in trauma patients at high risk for venous thromboembolism: a randomized pilot trial.

J Thromb Thrombolysis 2021 May 12. Epub 2021 May 12.

UC Health - University of Cincinnati Medical Center, 234 Goodman Street, Mail Location 0740, Cincinnati, OH, USA.

The impact of antithrombin III activity (AT-III) on prophylactic enoxaparin anti-factor Xa concentration (anti-Xa) is unknown in high-risk trauma patients. So too is the optimal anti-Xa-adjusted enoxaparin dosage. This prospective, randomized, pilot study sought to explore the association between AT-III and anti-Xa goal attainment and to preliminarily evaluate two enoxaparin dosage adjustment strategies in patients with subprophylactic anti-Xa. Read More

View Article and Full-Text PDF

Return to High Altitude after Recovery from Coronavirus Disease 2019.

High Alt Med Biol 2021 May 11. Epub 2021 May 11.

Division of Pulmonary and Critical Care Medicine, Intermountain Medical Center and the University of Utah, Salt Lake City, Utah, USA.

Luks, Andrew M. and Colin K. Grissom. Read More

View Article and Full-Text PDF

Non-operative management of blunt splenic trauma: evolution, results and controversies.

Rev Col Bras Cir 2021 7;48:e20202777. Epub 2021 May 7.

- Hospital das Clínicas da Universidade de São Paulo, Departamento de Cirurgia - São Paulo - SP - Brasil.

The spleen is one of the most frequently affected organs in blunt abdominal trauma. Since Upadhyaya, the treatment of splenic trauma has undergone important changes. Currently, the consensus is that every splenic trauma presenting with hemodynamic stability should be initially treated nonoperatively, provided that the hospital has adequate structure and the patient does not present other conditions that indicate abdominal exploration. Read More

View Article and Full-Text PDF

Unilateral deep vein thrombosis with gangrene involving the ascending aorta with sepsis and pulmonary thromboembolism -a pertinent cutaneous marker of severity of COVID -19.

J Cosmet Dermatol 2021 May 12. Epub 2021 May 12.

Department Of Critical Care Medicine, Atal Bihari Vajpayee Institute Of, Medical Sciences And Dr Ram Manohar Lohia Hospital, Newdelhi, 110001.

While myriad skin manifestations have been reported with COVID they are insignificant as compared to the number of cases and do not indicate specificity as the studies that report them have either been based on telephonic consultation or have not been compared with case control analysis from a normal skin OPD or IPD referral population. The most feared complication of COVID-19 is the combination of coagulopathy and thromboembolism which is consequent to thrombo-inflammation and a heightened prothrombotic state. It is exaggerated in severe COVID associated with sepsis and skin manifestations that correlate with severity are more useful to clinicians. Read More

View Article and Full-Text PDF

Impact of oral anticoagulant choice for the secondary prevention of venous thromboembolism on the risk of inpatient bleeding.

Res Pract Thromb Haemost 2021 May 4;5(4):e12514. Epub 2021 May 4.

Division of Epidemiology and Community Health University of Minnesota Minneapolis MN USA.

Background: Randomized trials suggest that direct oral anticoagulants (DOACs) are at least as effective as warfarin for primary treatment of VTE and that bleeding risk may be lower for some DOACs relative to warfarin. However, there is very little information regarding potential bleeding risks for DOACs versus warfarin in secondary prevention of VTE.

Objective: The aim of this study was to compare rates of bleeding events resulting in inpatient admissions between individuals taking apixaban, rivaroxaban, and warfarin for secondary prevention of VTE during the period 2013-2017. Read More

View Article and Full-Text PDF

Reproductive issues in women on direct oral anticoagulants.

Res Pract Thromb Haemost 2021 May 3;5(4):e12512. Epub 2021 May 3.

Thrombosis Research Unit Department of Medicine I Division Haematology University Hospital "Carl Gustav Carus" Dresden Dresden Germany.

Direct oral anticoagulants (DOACs) are replacing warfarin and other vitamin K antagonists for a wide range of indications. Advantages of DOAC therapy are fewer food and drug interactions and fixed dosing without routine laboratory monitoring, making DOACs the perfect choice especially for younger patients, in whom the main indication for anticoagulation is prevention and treatment of venous thromboembolism (VTE). Although DOACs are safer and much more convenient than other anticoagulant alternatives, their profile may have drawbacks, especially for younger female patients in whom reproductive issues need special considerations. Read More

View Article and Full-Text PDF

Perioperative management of anticoagulant therapy.

Innov Surg Sci 2019 Dec 18;4(4):144-151. Epub 2019 Jul 18.

Department of General, Visceral, Transplantation, Vascular and Pediatric Surgery, University Hospital Würzburg, Wüerzburg, Germany.

About 10% of patients taking a chronic, oral anticoagulant therapy require an invasive procedure that can be associated with an increased risk for peri-interventional or perioperative bleeding. Depending on the risk for thromboembolism and the risk for bleeding, the physician has to decide whether the anticoagulant therapy should be interrupted or continued. Patient characteristics such as age, renal function and drug interactions must be considered. Read More

View Article and Full-Text PDF
December 2019

[On-pump Beating Pulmonary Embolectomy for Acute Pulmonary Thromboembolism].

Kyobu Geka 2021 Feb;74(2):94-98

Department of Cardiovascular Surgery, Uji-Tokushukai Medical Center, Uji, Japan.

Background: Acute massive pulmonary embolism is a life-threatening disease and the reported rate of mortality is 52%.It is often treated with anticoagulation therapy or thrombolysis, but in case of critically ill patients with shock or cardiac arrest, its effect is limited. Surgical embolectomy is a treatment option for patients with hemodynamic instability. Read More

View Article and Full-Text PDF
February 2021

Consideration of pulmonary thromboembolism in paediatric patients presenting to the emergency department with abdominal pain.

BMJ Case Rep 2021 May 11;14(5). Epub 2021 May 11.

Emergency Department, NHS Lanarkshire, East Kilbride, UK.

Venous thromboembolism (VTE) is a recognised complication of lower limb trauma in adult patients and classically presents with cardiopulmonary symptoms. However, the risk of VTE and its presenting signs and symptoms are less well documented in the paediatric population. We report the case of a child who presented to our emergency department with abdominal pain 2 weeks after lower limb fracture, who was subsequently found to have a pulmonary thromboembolism (PTE). Read More

View Article and Full-Text PDF

Cerebral Venous Thrombosis Associated with COVID-19 Infection: An Observational, Multicenter Study.

Cerebrovasc Dis Extra 2021 May 11;11(2):55-60. Epub 2021 May 11.

Rashid Hospital, Dubai, United Arab Emirates.

Background And Purpose: Coronavirus disease 2019 (CO-VID-19) has an increased propensity for systemic hypercoagulability and thromboembolism. An association with cerebrovascular diseases, especially cerebral venous thrombosis (CVT), has been reported among these patients. The objective of the present study was to identify risk factors for CVT as well as its presentation and outcome in COVID-19 patients. Read More

View Article and Full-Text PDF

Expert Review: Prevention of Obstetric Venous Thromboembolism.

Am J Obstet Gynecol 2021 May 8. Epub 2021 May 8.

Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, Columbia University Irving Medical Center, New York, NY.

Venous thromboembolism (VTE) represents a persistent proportionate cause of maternal mortality in the United States accounting for 9% to 10% of maternal deaths. Given that overall maternal mortality rose >40% since the late 1990s, it is likely absolute VTE mortality risk increased as well. This persistent risk may be secondary to increases in broad population-based risk factors for VTE such as obesity and cesarean delivery. Read More

View Article and Full-Text PDF

Risk of venous thromboembolism and endocrine therapy in older women with breast cancer in the United States.

Blood Coagul Fibrinolysis 2021 May 10. Epub 2021 May 10.

Division of Hematology, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.

Our aim was to evaluate the risk of venous thromboembolism (VTE) with tamoxifen and aromatase inhibitor in older women with breast cancer in the United States. The SEER-Medicare-linked database (2007--2013) was used for women of at least 65 years of age diagnosed with breast cancer in the United States. Logistic regression was used to examine unadjusted and adjusted odds ratios (OR) with 95% confidence intervals (CIs) for the risk of VTE. Read More

View Article and Full-Text PDF

Sex-influence on the time in therapeutic range (TTR) during oral anticoagulation with coumarin derivatives: systematic review and meta-analysis.

Br J Clin Pharmacol 2021 May 11. Epub 2021 May 11.

Faculdade de Farmácia, Universidade Federal de Minas Gerais, Av. Pres. Antônio Carlos, 6627, Pampulha, Belo Horizonte, Minas Gerais, 31270-901, Brazil.

Aim: We sought to investigate the association between sex and oral anticoagulation control employing coumarin derivatives.

Methods: Electronic sources were MEDLINE, Biblioteca Virtual em Saúde (BVS), The Cumulative Index to Nursing and Allied Health Literature (CINAHL), EMBASE, Cochrane Central and Web of Science. Inclusion criteria were: observational and experimental studies; age ≥18 years; both sexes; treatment with any coumarin derivative for ≥3 months; any indication of long-term use; quality of oral anticoagulation measured by time in therapeutic range (TTR). Read More

View Article and Full-Text PDF

COVID-19 and Cardiovascular Diseases.

Adv Exp Med Biol 2021 ;1318:263-291

Department of Cardiology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.

We herein seek to expound on up-to-the-minute information regarding cardiovascular disease in the era of coronavirus disease 2019 (COVID-19) by highlighting acute myocardial injury caused by COVID-19 and probing into its pathophysiology, clinical signs, diagnostic tests, and treatment modalities. We aim to share the latest research findings vis-à-vis cardiovascular disease patients with confirmed or suspected COVID-19 on the association between hypertension and this infectious disease along with the relevant recommendations; describe the mechanism of coronary artery disease in such patients together with the necessary measures in the setting of non-ST-segment elevation acute coronary syndrome, ST-segment elevation myocardial infarction, and chronic coronary syndrome; discuss tachy- and bradyarrhythmias in the COVID-19 setting alongside their treatments; elucidate coagulopathies, venous thromboembolism, and its prophylactic measures in the context of this infection; set out the cardiopulmonary resuscitation protocol as well as the pertinent safety concerns during the current pandemic; and, finally, explicate drug-drug interactions between COVID-19 and cardiovascular medication in hypertension, acute coronary syndrome, heart failure, venous thromboembolism, and arrhythmias. Read More

View Article and Full-Text PDF

Antiphospholipid antibodies in critically ill COVID-19 patients with thromboembolism: cause of disease or epiphenomenon?

J Thromb Thrombolysis 2021 May 10. Epub 2021 May 10.

School of Dentistry, University of Utah Health, Salt Lake City, Utah, USA.

Coronavirus 2019 disease (COVID-19) is associated with coagulation dysfunction that predisposes patients to an increased risk for both arterial (ATE) and venous thromboembolism (VTE) and consequent poor prognosis; in particular, the incidence of ATE and VTE in critically ill COVID-19 patients can reach 5% and 31%, respectively. The mechanism of thrombosis in COVID-19 patients is complex and still not completely clear. Recent literature suggests a link between the presence of antiphospholipid antibodies (aPLs) and thromboembolism in COVID-19 patients. Read More

View Article and Full-Text PDF

Cardioembolic stroke in the setting of multiple left ventricular thrombi.

BMJ Case Rep 2021 May 10;14(5). Epub 2021 May 10.

Cardiology, University of Florida College of Medicine - Jacksonville, Jacksonville, Florida, USA.

View Article and Full-Text PDF

Diseases and Complications of the Puerperium.

Dtsch Arztebl Int 2021 Jun;118(Forthcoming)

Background: In terms of maternal morbidity and mortality, the puerperium is just as significant as pregnancy and childbirth. Nearly half of all maternal deaths occur in the time after delivery.

Methods: This review is based on pertinent articles in English and German from the years 2000- 2020 that were retrieved by a selective search in MEDLINE and EMBASE, as well as on the available guidelines in English and German and on German-language textbooks of obstetrics. Read More

View Article and Full-Text PDF

Predicting venous thromboembolism in hospitalized trauma patients: a combination of the Caprini score and data-driven machine learning model.

BMC Emerg Med 2021 May 10;21(1):60. Epub 2021 May 10.

Trauma Center of West China Hospital/West China School of Medicine, Sichuan University, Guo Xue Road 37#, Chengdu, 610041, China.

Background: Venous thromboembolism (VTE) is a common complication of hospitalized trauma patients and has an adverse impact on patient outcomes. However, there is still a lack of appropriate tools for effectively predicting VTE for trauma patients. We try to verify the accuracy of the Caprini score for predicting VTE in trauma patients, and further improve the prediction through machine learning algorithms. Read More

View Article and Full-Text PDF

Upper Extremity Deep Vein Thrombosis: Current Knowledge and Future Directions.

Semin Thromb Hemost 2021 May 10. Epub 2021 May 10.

Monash Haematology, Monash Health, Melbourne, Australia.

Upper extremity deep vein thrombosis (UEDVT) has been increasing in incidence due to the escalating use of central venous catheters such as peripherally inserted central catheters. UEDVT can be primary idiopathic or secondary to pacemaker leads, intravascular catheters or cancer. In comparison to conventional venous thromboembolism such as lower limb deep vein thrombosis or pulmonary embolism the risk factors, investigations, and management are not well defined. Read More

View Article and Full-Text PDF

Community-Onset Venous Thromboembolism in Children: Pediatric Emergency Medicine Perspectives.

Semin Thromb Hemost 2021 May 10. Epub 2021 May 10.

Division of Hematology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Pediatric venous thromboembolism (VTE) is a condition increasingly encountered by emergency medicine physicians. Unfortunately, despite increased incidence, the diagnosis of pediatric VTE relies on a high index of suspicion from clinicians. Delays in diagnosis and initiation of treatment can lead to poor outcomes in children, including an increased risk of mortality from pulmonary embolism, increased risk of VTE recurrence, and the development of the post-thrombotic syndrome. Read More

View Article and Full-Text PDF

Profile of Patients with Isolated Distal Deep Vein Thrombosis versus Proximal Deep Vein Thrombosis or Pulmonary Embolism: RE-COVERY DVT/PE Study.

Semin Thromb Hemost 2021 May 10. Epub 2021 May 10.

Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Isolated distal deep vein thrombosis (IDDVT) is presumed to be more benign than proximal DVT (PDVT) or pulmonary embolism (PE), suggesting a need for different management approaches. This subgroup analysis of the RE-COVERY DVT/PE global, observational study investigated patient characteristics, hospitalization details, and anticoagulant therapy in patients with IDDVT in real-world settings in 34 countries enrolled from January 2016 to May 2017. Data were analyzed descriptively according to the type and location of the index venous thromboembolism (VTE): IDDVT, PDVT ± distal DVT (DDVT), and PE ± DVT. Read More

View Article and Full-Text PDF

Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Pediatric Venous Thromboembolism Treatment and Thromboprophylaxis: A Systematic Review of the Literature.

Semin Thromb Hemost 2021 May 10. Epub 2021 May 10.

Johns Hopkins All Children's Institute for Clinical and Translational Research, St. Petersburg, Florida.

Venous thromboembolism (VTE) in children can lead to significant morbidity and mortality. Traditionally, treatment for thrombotic events in pediatric patients has been limited mainly to unfractionated heparin, low-molecular-weight heparin (LMWH), or vitamin K antagonists. Since the first non-vitamin K antagonist oral anticoagulant (NOAC) was approved for adult use, these agents have gained popularity for a variety of indications. Read More

View Article and Full-Text PDF

Arterial Thrombosis in Patients with Antiphospholipid Syndrome: A Review and Meta-Analysis.

Semin Thromb Hemost 2021 May 10. Epub 2021 May 10.

Department of Medicine, Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario, Canada.

There is a scarcity of high-quality randomized controlled trials (RCTs) comparing antithrombotic regimens for secondary prevention of arterial thrombosis (AT) in antiphospholipid syndrome (APS). We reviewed different antithrombotic regimens used for this purpose. We searched for studies on management of AT in APS on PubMed and Web of Science. Read More

View Article and Full-Text PDF

Efficacy and safety of direct oral anticoagulants for treatment of left ventricular thrombus; a systematic review.

Acta Cardiol 2021 May 10:1-5. Epub 2021 May 10.

Department of Internal Medicine, Western Michigan University Homer Stryker M.D. School of Medicine, Michigan State University, Kalamazoo, MI, USA.

Introduction: Left ventricular thrombus (LVT) is a well-recognised complication of ischaemic and non-ischaemic heart disease. The incidence of this complication has drastically reduced due to reperfusion therapies. Current guidelines recommend using warfarin for at least three months. Read More

View Article and Full-Text PDF

Cardiovascular Toxicities of Antiangiogenic Tyrosine Kinase Inhibitors: A Retrospective, Pharmacovigilance Study.

Target Oncol 2021 May 10. Epub 2021 May 10.

Leviev Heart Center, Sheba Medical Center, Ramat Gan, Israel.

Background: Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) are an essential therapeutic option in the management of various solid tumors, particularly renal cell carcinoma (RCC). However, post-marketing data regarding their potential cardiovascular toxicities are scant.

Objective: To identify and characterize cardiovascular adverse events (CVAEs) of VEGFR-TKIs indicated for RCC. Read More

View Article and Full-Text PDF

Incidence and risk factors for symptomatic venous thromboembolism following anterior cruciate ligament reconstruction.

Knee Surg Sports Traumatol Arthrosc 2021 May 10. Epub 2021 May 10.

Rush University Medical Center, 1611 W Harrison St, Chicago, IL, 60612, USA.

Purpose: To determine the incidence of symptomatic venous thromboembolism (VTE) following anterior cruciate ligament (ACL) reconstruction using a large national database and to identify corresponding independent risk factors.

Methods: The Humana administrative claims database was reviewed for patients undergoing ACL reconstruction from 2007 to 2017. Patient demographics, medical comorbidities, as well as concurrent procedures were recorded. Read More

View Article and Full-Text PDF

Cesarean delivery at term for non-reassuring fetal heart rate tracing: risk factors and predictability.

J Matern Fetal Neonatal Med 2021 May 9:1-7. Epub 2021 May 9.

Department of Obstetrics, Gynecology, and Reproductive Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.

Objective: To delineate risk factors for adverse outcomes among those who underwent cesarean delivery (CD) for non-reassuring fetal heart rate tracing (NRFHT) and ascertain whether neonatal or maternal morbidity can be predicted accurately.

Methods: The Consortium on Safe Labor Database was utilized for this secondary analysis. Inclusion criteria were non-anomalous, singleton gestations between 37. Read More

View Article and Full-Text PDF

SARS-CoV-2-related outcomes after surgical procedures on SARS-CoV-2-positive patients in a large, urban, safety net medical center.

Surg Open Sci 2021 May 3. Epub 2021 May 3.

Los Angeles County + University of Southern California (LAC + USC) Medical Center, Los Angeles, CA.

Background: Beginning on March 16, 2020, non-urgent scheduled operations at a large, urban, safety net medical center were canceled. The purpose of this study was to determine complications associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection for all operations done from March 16-June 30, 2020.

Study Design: This study was a single-institution, retrospective observational analysis of data for all surgical procedures and all SARS-CoV-2 tests done in the medical center from March 16-June 30, 2020. Read More

View Article and Full-Text PDF